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A B S T R A C T
Purpose: To explore the association between the use of neuroactive drugs and reports of epileptic
seizures.
Material: Using the WHO adverse drug reactions (ADR) database, VigiBase, we surveyed reports of
suspected seizures from 1968 until February 2006. Case reports of ADRs, that were classiﬁed as
convulsions were collected and compared to the total number of ADRs reported.
Results: The total number of ADRswas 7,375,325. The number of convulsive eventswas 71,471. The ratio
of convulsive ADRs to the total number of ADRs reported for each drug was evaluated and expressed as a
percentage. The 10 drugs most frequently associated with convulsive ADRs were maprotilene (14.42%),
escitaloprame (9.78%), buproprione (9.49%), clozapine (9.0%), chlorprothiexene (8.89%), amoxapine
(8.74%), donepezil (8.40%), rivastigmine (6.41%), quetiapine (5.90%) and trimipramine (5.69%).
Conclusions: Based on the reports in VigiBase, ADR reports relating to antidepressants, antipsychotic and
cholinomimetic drugs included seizures more often than other neuroactive drugs.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Many compounds that act on the nervous system are known to
reduce the seizure threshold and provoke epileptic seizures.
Although these adverse events have been described for almost
every drug available, few systematic reviews have been published.
The present study explored the occurrence of suspected seizure
adverse events in relation to treatmentwith neuroactive drugs, in a
large, global safety database.
Following the thalidomide disaster in the 1960s, the WHO
Program for International DrugMonitoringwas set up, with the aim
of collecting and storing spontaneously reported suspected adverse
drug reaction (ADR) reports inan international database. Since1978,
the Uppsala Monitoring Centre has maintained the WHO-ADR
database, VigiBase. Case reports, are recorded in a common format,
processedandstored inVigiBase.AnADR isdeﬁnedasa response toa
drug, which is noxious, and unintended; the ADR occurs at doses
normally used in human patients for the prophylactic, diagnosis, or
therapyof disease, or for themodiﬁcationof physiological functions.
These reports are forwarded spontaneously to the national
pharmacovigilance centres for assessment and coding. The main
aim of VigiBase is to detect previously unknown ADRs, so-called* Corresponding author at: Department of Neuroscience, Neurology, Uppsala
University Hospital, SE-751 85 Uppsala, Sweden. Tel.: +46 18 6115039;
fax: +46 18 6115027.
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doi:10.1016/j.seizure.2009.11.005signals of unwanted side effects. The database is a unique source of
international ADR information, andwhen this studywas carried out
(February 2006), the database contained almost 3.6 million case
reports from 79 different countries. WHO-ADR data are not
homogenous with respect to origin of the ADR or the probability
that a particular drug causes a given adverse reaction. However,
these reports have proven to be useful in the early detection of
signals of unwanted drug side effects.1 WHO deﬁnes a signal as
reported information on a possible causal relationship between an
ADR and a drug, when the relationship was previously unknown or
has been documented incompletely. Usually more than one single
report is required to generate a signal of unwanted side effects, and
the signal is also dependent on the seriousness of the event and the
qualityof the information.2 Previously,methods similar toours have
been used to study drug-related adverse events such in VigiBase, as
headache3 and sexual dysfunction.4
The purpose of the present study was to review VigiBase, for
drugs belonging to the Anatomical Therapeutic Chemical (ATC)
Classiﬁcation System group ‘‘nervous system’’ and explore their
association with reports of seizures. In this article, seizures and
convulsions will be used as synonymous terms.
2. Methods
VigiBase was searched for spontaneously reported cases of
suspected ADRs including the following WHO-ART terms:
convulsions, aggravated convulsions, convulsions grand mal, and
convulsions local. Individuals who experienced more than onevier Ltd. All rights reserved.
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classiﬁed as an agent within the ‘nervous system’ (ACT groups
N01-7) were collected and analysed with the terms of interest.
Anaesthetic (N01) and analgesic (N02A and N02B) drugs were not
included in this study since reports of convulsions are difﬁcult to
interpret in situations inwhich these drugs are indicated explicitly.
Antiepileptic drugs (AEDs, ATC group N03) were also excluded
because of the inherent difﬁculty in determining if a reported
convulsion was caused by insufﬁcient AED-medication or was an
actual ADR. Drugs used for migraine (ATC group N0C2) were
included, even though their main action is not directly on the
central nervous system. Except in one case (L-dopa with
decarboxylase inhibitor), reports were used only when the drug
in questionwas given as single-component therapy. Consequently,Table 1
Neuroleptics. Reports of suspected drug-related seizures in WHO VigiBase, 1968–2006
Drug name ATC-code Year of ﬁrst report Total no. ADRs
Chlorpromazine NO5AA 1968 6024
Chlorprothiexene NO5AF 1968 461
Fluphenazine NO5AB 1968 2707
Levomepromazine NO5AA 1968 2207
Perphenazine NO5AB 1968 1601
Procloperazine NO5AB 1968 4376
Alimemazine NO5AA 1968 574
Haloperidol NO5AD 1968 10,046
Doxepine NO6AA 1969 3212
Flupentixol NO5AF 1969 1753
Dixyrazine NO5AB 1970 142
Dosulepine NO6AA 1971 1673
Melperone NO5AD 1972 319
Zuclopenthizol NO5AF 1979 962
Drugs with reports of convulsions expressed as percentage of total number of adverse
Table 3
Antidepressants. Reports of suspected drug-related seizures in WHO Vigibase 1968–20
Drug name ATC-code Year of ﬁrst report Total no. ADRs
Amitriptyline NO6AA 1968 8545
Nortriptyline NO6AA 1968 2828
Trimipramine NO6AA 1968 1150
Clomipramine NO6AA 1969 5960
Maprotilene NO6AA 1975 3243
Mianserin NO6AB 1977 4501
Trazadone NO6AX 1978 5595
Amoxapine NO6AA 1981 1384
Citalopram NO6AB 1982 11,107
Fluvoxamine NO6AB 1983 6974
Fluoxetine NO6AB 1986 50,403
Paroxetine NO6AB 1988 34,078
Moclobemide NO6AG 1988 3424
Sertraline NO6AB 1991 29,375
Venlafaxine NO6AX 1994 16,641
Nefazodone NO6AX 1995 8203
Mirtazapine NO6AX 1996 5748
Reboxitine NO6AX 1998 1461
Ziprasidone NO5AE 2001 2534
Escitaloprame NO6AB 2002 1994
Duloxetine NO6AX 2004 1201
Bupropion NO7BA 1985 28,170
Drugs with reports of convulsions expressed as percentage of total number of adverse
Table 2
Atypical neuroleptics. Reports of suspected drug-related seizures in WHO Vigibase 196
Drug name ATC-code Year of ﬁrst report Total no. ADRs
Clozapine NO5AH 1974 41 735
Risperidone NO5AX 1993 16 808
Quetiapine NO5AH 1995 4 289
Olanzapine NO5AH 1997 14 261
Aripiprazol NO5AX 2001 3 207
Drugs with reports of convulsions expressed as percentage of total number of adverseATC groups included were: neuroleptics and atypical neuroleptics
(N05), antidepressants (N06), triptanes (N02), anti-Parkinson’s
drugs (N04), anxiolytics (N05) and miscellaneous neurotropic
drugs (NO6B and D).
The reports were sorted according to the drug’s generic name.
The year of the ﬁrst report, total number of ADRs for the drug in
question, number of convulsive ADRs and the percentage of the
total number of ADRs, that were convulsions (convulsive ADRs/
total ADRs) were scrutinised.
3. Results
In total, there were 7,375,325 ADRs reported from the
3.6 million case reports in VigiBase, and 71,471 included.
Total no. convulsions Percentage convulsions of total no. of ADRs
148 2.46
41 8.89
84 3.49
94 4.26
51 3.19
137 3.13
29 5.05
329 3.27
119 3.70
50 2.85
2 1.40
82 4.90
13 4.08
46 4.18
drugs exceeding 5% are given in italic.
06.
Total no. convulsions Percentage convulsions of total no. of ADRs
342 4.00
111 3.93
66 5.69
334 5.60
468 14.43
159 3.53
144 2.57
121 8.74
471 4.26
303 4.34
1689 3.35
991 2.90
77 2.25
949 3.23
797 4.79
121 1.48
243 4.23
18 1.23
96 3.79
195 9.78
36 3.00
2670 9.48
drugs exceeding 5% are given in italic.
8–2006.
Total no. convulsions Percentage convulsions of total no. of ADRs
3758 9.00
618 3.68
253 5.90
700 4.91
83 2.59
drugs exceeding 5% are given in italic.
Table 4
Antimigraine drugs. Reports of suspected drug-related seizures in WHO Vigibase 1968–2006.
Drug name ATC-code Year of ﬁrst report Total no. ADRs Total no. convulsions Percentage convulsions of total no. of ADRs s
Dihydro-ergotamine NO2CA 1968 830 20 2.41
Ergotamin NO2CA 1969 312 6 1.92
Sumatriptan NO2CC 1991 11,075 189 1.71
Naratriptan NO2CC 1997 287 6 2.09
Zolmitriptan NO2CC 1998 718 12 1.67
Rizatriptan NO2CC 1999 398 11 2.76
Almotriptan NO2CC 2001 64 1 1.56
Elitriptan NO2CC 2003 359 4 1.11
Table 5
Anti-Parkinson’s drugs. Reports of suspected drug-related seizures in WHO Vigibase 1968–2006.
Drug name ATC-code Year of ﬁrst report Total no. ADRs Total no. convulsions Percentage convulsions of total no. of ADRs
Omphenadrine NO4BA 1968 633 17 2.69
Trihexyphenidyl NO4AA 1968 178 24 2.04
Biperidine NO4BA 1969 742 39 5.26
Levodopaa NO4BA 1970 5297 6 0.11
Bromocriptine NO4BC 1977 3798 208 5.48
Selegiline NO4BD 1980 1298 34 2.62
Carbegoline NO4BC 1990 701 9 1.28
Tolcapone NO4BX 1996 674 7 0.73
Ropinerole NO4BC 1995 1017 25 2.46
Pramipexole NO4BC 1998 1001 12 1.20
Entacapone NO4BX 1999 545 4 0.73
Drugs with reports of convulsions expressed as percentage of total number of adverse drugs exceeding 5% are given in italic.
a Levodopa+decarboxylase inhibitors.
Table 6
Anxiolytic drugs. Reports of suspected drug-related seizures in WHO Vigibase 1968–2006.
Drug name ATC-code Year of ﬁrst report Total no. ADRs Total no. convulsions Percentage convulsions of total no. of ADRs
Diazepam NO5BA 1968 8236 206 2.50
Chlormethiazole NO5CM 1986 327 4 1.22
Nitrazepam NO5CD 1968 105 14 1.33
Oxazepam NO5BA 1969 1775 63 3.55
Propiomazine NO5CM 1971 476 5 3.50
Lorazepam NO5BA 1973 5885 291 4.94
Flunitrazepam NO5CD 1976 1054 43 2.58
Triazolam NO5CD 1978 1668 65 1.63
Alprazolam NO5BA 1983 7261 403 5.55
Midazolam NO5CD 1984 3966 260 5.27
Buspirone NO5BE 1987 4691 113 2.41
Zolpiclone NO5CF 1987 4936 45 1.58
Zolpidem NO5CF 1988 4908 139 2.83
Zaleplon NO5CF 2000 2854 9 1.89
Drugs with reports of convulsions expressed as percentage of total number of adverse drugs exceeding 5% are given in italic.
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included more than one ADR. Convulsions constituted 0.97% of
all ADRs and were recorded in 1.99% of the case reports. For
individual drugs, the number of reports of convulsions isTable 7
Miscellaneous neurotropic drugs. Reports of suspected drug-related seizures in WHO V
Drug name ATC-code Year of drug introduction Total no. ADR
Methylphenidate NO6BA 1969 4496
Modaﬁnil NO6BA 1997 816
Piracetam NO6BX 1975 739
Donepezil NO6DA 1997 4226
Rivastigmin NO6DA 1998 2092
Galantamine NO6DA 1976 1100
Memantine NO6DX 1984 2132
Neostigmine NO7AA 1968 222
Pyridostigmine NO7AA 1972 247
Pilocarpine NO7AX 1969 749
Naltrexone NO7BB 1985 681
Buprenorphine NO7BC 1978 3493
Methadone NO7BC 1968 3096
Drugs with reports of convulsions expressed as percentage of total number of adverseexpressed as a percentage of the total number of ADR reports
for that particular drug. The results are presented in Tables 1–7
according to the drug’s proposed mechanism of action and year
of the ﬁrst ADR report.igibase 1968–2006.
s Total no. convulsions Percentage convulsions of total no. of ADRs
175 3.89
38 4.66
23 3.11
355 8.40
134 6.41
59 5.36
87 4.08
6 2.70
4 1.62
5 0.67
17 2.50
39 1.12
52 1.68
drugs exceeding 5% are given in italic.
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convulsions varied from 1.4 to 8.89% of the total number of ADRs
for a particular drug. In this group chlorprothiexene had the
highest ﬁgure (8.89%), followed by alimemazine (5.05%). The
atypical neuroleptics had a range of 2.59–9.0%. Clozapine had the
largest proportion of convulsive reports (9.0%). Antidepressants
ranged from 1.3 to 14.43%. In this group maprotilene had 14.43%,
escitaloprame 9.78%, amoxapine 8.74%, trimipramine 5.69% and
clomipramine 5.6%.
Reports of convulsions in the triptans varied from 1.11 to 2.76%
Drugs used in Parkinson’s disease had a range of 0.11–5.48%. In this
group the greatest proportions was attributed to the dopamine
agonist, bromocriptine (5.48%). Among miscellaneous neurotropic
drugs, convulsions were noted for the acetylcholinesterase
inhibitors: donepezil (8.40%) and rivastigmine (6.41%).
4. Discussion
We used the spontaneous ADR database to identify epileptic
events that occurred in relation to the reported drug treatment.
Despite the limitations of spontaneous reporting, most notably
underreporting, no clear link to drug exposure data, lack of control
group, potential biases in reporting, missing and incomplete data,
and unknown causality, uneven quality of information provided,
and inﬂuences by media and publicity, a high number of reports of
a similar nature may identify important ADRs.
Unfortunately, from our study, it is not appropriate to compare
a drug with another concerning the number of convulsive reports,
since the total number of patients who were treated with a
particular drug is not known and it is impossible to calculate the
true prevalence of ADRs. For each drug, the reported numbers of
convulsive ADRs were assessed relative to the total number of ADR
reports. Previous studies have used the ratio expressed as: speciﬁc
ADR/total ADR.4,5 In the present study, we found that this ratio was
1.99% for convulsions. We built up this discussion on the
assumption that for any given drug, a high ADR/total ADR ratio
indicates a high risk for inducing seizures. Additionally, tentative
mechanisms are discussed.
Incidence studies have suggested that the risk for psychosis
may be 6–12-fold greater in patients with epilepsy than in the
general population.6 Therefore, it is expected that the usage of
antipsychotic drugs is more frequent in a population with high
seizure susceptibility which contributes to an increased number of
reported convulsions.
The major antipsychotic drugs are the neuroleptics, which act
mainly by blocking dopamine receptors. These drugs have been
associated traditionally with a high risk of seizures. Different
dopamine receptors mediate opposing inﬂuences on neuronal
excitability and seizure susceptibility. Blocking the D2 receptor is
associated with seizure precipitation,7 while D1 antagonists are
known to protect against seizures8. The neuroleptics have variable
net effects on seizure threshold, probably because each drug has a
different afﬁnity for each of the dopamine receptors. Among the
ﬁrst-generation antipsychotic medications (typical antipsycho-
tics), chlorprothiexene, which exerts its effects on D1, D2, D3,
serotoninergic and cholinergic receptors, had a relatively large
proportion (8.89%) of reported convulsions. Shortly after becoming
available clinically, chlorpromazine was noticed to be associated
with generalised seizures consistent with the incidence found in
this study. Later publications however have shown an incidence of
seizures of <2%.9 Other typical neuroleptics in this study had a
relatively low potential for convulsive adverse events in accor-
dance with the estimates in previous literature.10 Alimemazine,
although structurally related to chlorpromazine, is a sedating
antihistamine used for allergic skin reactions and sedation. Five
percent of the ADRs reported for alimemazine were convulsions.However, it may be hazardous to draw any ﬁrm conclusion about
the relationship between alimemazine and seizure induction
because it is often used to treat alcoholism.
Both typical and atypical antipsychotic medication may
cause seizures. In the present study, clozapine was the atypical
antipsychotic that was most frequently associated with seizures.
Our data are in agreement in previous studies in which
clozapine-induced seizures were estimated to occur in 3.5% of
patients in pre-marketing trials and showed a predicted 5%
cumulative risk at 1 year.11 The mechanism by which clozapine
lowers the seizure threshold is not fully understood. Clozapine
displays strong afﬁnity to several subtypes of dopamine
receptors. It has been proposed that clozapine and clozapine-
related drugs (olanzapine and quetiapine) have selectivity for
mesolimbic dopamine receptors, which may account for their
proconvulsive effects.12 According to VigiBase data, risperidone,
which has a low afﬁnity for D2 receptors, caused less convulsive
ADRs than clozapine did. This concurs with the results of pre-
marketing monitoring.13
Antidepressant drugs are known to have a proconvulsive effect.
Mood and affect disorders occur more frequently in persons with
epilepsy as compared with the general population; this necessi-
tates the use of antidepressant drugs in this group.14 Depression in
itself may cause seizures thereby contributing to an increased
number of ADRs.15 The incidence of seizure adverse events range
from 0.1 to 4.0% in the literature in patients treated with
antidepressants.16 We found high numbers for convulsive ADRs
in the antidepressant group, most frequently for maprotilene,
amoxapine, imipramine, buproprion and escitalopram. Differences
in sampling size may explain the higher frequency. However,
maprotilene, buproprione, and amoxapine have been associated
previously with a greater seizure risk than other antidepres-
sants.17,18 The mechanisms through which antidepressants alter
neuronal excitability and modify seizure threshold are still largely
unknown. Antidepressants act mainly by blocking the re-uptake of
monoamines. Both animal and human data have shown that
blocking the re-uptake of norepinephrine and/or serotonin has an
anticonvulsant effect19. The convulsive properties of antidepres-
sants have been suggested to be the result of their possible local
anaesthetic or anticholinergic effect.20 It has been proposed that
selective serotonin re-uptake inhibitors (SSRIs) are less likely to
cause seizures than cyclic antidepressants.21 On the other hand,
seizures have been associated with SSRIs in previous studies of
adverse events as in the case of escitaloprame.22
Although distinct in their pathogenesis, migraine headaches
and epilepsy may coexist and interrelate in a number of ways.
Patients with migraine aura may sometimes progress to have clear
epileptic events.23 In the literature, however, there are very few
reports on seizures provoked by migraine medications. This is not
surprising considering the fact that the ergot derivatives and
triptanes exert their effect by direct stimulation of serotonin-
receptors outside the brain in extra-cranial vessels. In VigiBase, it
was a low number of reports of convulsions in response to
migraine treatment.
Historically, dopamine is known to have an anticonvulsant
effect. However, there are many examples of dopamine agonists
with proconvulsive properties. This is attributable to the different
effect of dopamine and its receptor subtypes; D1 being procon-
vulsive and D2 anticonvulsive.
24 The majority of anti-Parkinson
drugs act by increasing dopaminergic transmission directly or
indirectly. Levodopa has been reported to lower, exacerbate or not
alter seizure threshold.24 Few reports in VigiBase of convulsions
and dopamine stimulation favour the view that levodopa has little
inﬂuence on seizure threshold. With the exception of bromocrip-
tine, stimulation of dopamine receptors directly by agonists also
seems to have little effect on seizure threshold. In VigiBase the
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explanation for this may be related to the use of bromocriptine for
suppression of lactation in postpartum women who are at risk for
developing hypertension and encephalopathy, in whom seizures
are part of the symptomatology. In addition, bromocriptine is used
for treatment of prolactinomas, which may extend into the
temporal lobes and cause seizures.
In the anxiolytic drugs, there were few reports of seizures in
relation to treatment with different benzodiazepines or chlo-
methiazole. The pharmacological effect of these drugs is mediated
mainly by increasing GABA, the major inhibitory neurotransmitter
in the brain. The fact that there have been some reports of
convulsions with benzodiazepines and chlomethiazole might be
related to drug withdrawal or use of the drugs in the treatment of
epilepsy.
Seizures can be induced or exacerbated by cholinomimetic
drugs. Seizure activity may also be a manifestation of Alzheimer’s
disease, which is the primary use of cholinomimetics. Cholinomi-
metics act by reversible inhibition of the enzyme acetylcholines-
terase and exert their therapeutic action by enhancing neuronal
cholinergic transmission. Cholinergic dysfunction25 and alteration
of nicotinic cholinergic mechanisms contribute to various forms of
central nervous system dysfunction such as seizures.26 In the
present study, donepezil and rivastigmine were associated with
relatively high numbers of convulsive adverse events. To the best
of our knowledge, there have so far been occasional but no
systematic reports of convulsive adverse events from donepezil or
rivastigmine in the literature.
Our analysis of the ADRs in VigiBase indicates that treatment
with neuroleptics, antidepressants and cholinomimetic drugs can
lower the seizure threshold and provoke seizures. Nonetheless, it
should be noted that these conclusions are based on uncontrolled,
retrospective case reports in patients who may have other risk
factors for epileptic seizures. Furthermore, the total number of
treated patients is not known. To properly evaluate different drugs
and their propensity to cause adverse events, such as seizures,
evidence-based medicine, with randomised, controlled trials are
needed. Unfortunately, these studies are not likely to appear in the
literature. Comprehensive spontaneous ADRs registries can be
used to give warning about safety issues and generate important
safety hypotheses that can be investigated and corroborated with
other knowledge.
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